PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced that the Company’s second Investigational New Drug (IND) application for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, has …